Amara Raja Energy & Mobility Ltd. announces a new order win

Capital Infusion Summary

On August 10, 2026, the Board of Directors of Amara Raja Energy & Mobility Limited (ARE&M) approved an additional capital infusion limit of Rs 500 Crores into its primary New Energy wholly-owned subsidiary, Amara Raja Advanced Cell Technologies Private Limited (ARACT) ^[1].

• Total Cumulative Board-Approved Limit: Following this tranche, the total cumulative approved investment limit for ARACT reached Rs 2,500 Crores, derived from the pre-existing sanction of Rs 2,000 Crores plus the incremental Rs 500 Crores ^[1].
• Actual Capital Deployed: Prior to this sanction, actual capital infused into ARACT stood at Rs 1,650.01 Crores as of Q1 FY27 (ended June 30, 2026) ^[2] (up from Rs 1,500 Crores as of FY26 ^[3] and Rs 1,400 Crores as of Q3 FY26 ^[4]). Full deployment of the newly approved Rs 500 Crore tranche would bring actual cumulative capital deployed into ARACT to Rs 2,150.01 Crores (derived from Rs 1,650.01 Crores actual ^[2] plus Rs 500 Crores newly sanctioned ^[1]).

• (Note: The Board simultaneously approved an additional Rs 50 Crores investment limit into Amara Raja Power Systems Limited, doubling its total approved limit from Rs 50 Crores to Rs 100 Crores ^[1]).*

---

Capital Investment vs Segment Capex Breakdown

---

Alignment with Disclosed New Energy Capex Outlays

The incremental Rs 500 Crore approval aligns directly with both near-term annual budgets and long-term strategic roadmaps for the New Energy business segment:

1. Near-Term FY27 Capex Outlay Alignment

• Annual Budget Envelope: For FY27, ARE&M outlined a total capital expenditure program of Rs 1,500 Crores to Rs 1,700 Crores ^[5]. Of this total, 70%–75%—amounting to Rs 1,100 Crores to Rs 1,200 Crores—is dedicated specifically to the New Energy sector ^[5], ^[8].
• Project Allocation: The fresh Rs 500 Crore authorization provides the equity/loan backing to fund ongoing construction and plant setups in Telangana ^[1], including: Commercial commissioning of the Customer Qualification Plant (CQP)** (operationalized in July 2026 with a 60 MWh capacity at an outlay of Rs 500 Crores) ^[6].
• Development of the 5 GWh integrated Battery Energy Storage Systems (BESS) facility at Divitipally (estimated capex outlay of Rs 280 Crores, targeted for completion by late FY27/2026-end) ^[9], ^[4].
• Initial infrastructure outlay for Giga 1 (the first 2 GWh commercial NMC cell line, targeted for June 2027 startup) ^[9], ^[3].

2. Phased Alignment with Long-Term New Energy Outlay

• Phase 1 Phasing: ARE&M's long-term plan targets a 16 GWh cell manufacturing capacity in Telangana by 2030–2032 with an aggregate planned capital outlay of Rs 9,500 Crores to Rs 10,000 Crores ^[9], ^[6], ^[7].
• Capital Tranching: The cumulative board sanction of Rs 2,500 Crores ^[1] represents approximately 25% to 26% of the total long-term project budget. This demonstrates a phased funding framework where ARE&M releases capital to ARACT as specific milestones (such as CQP commissioning and BESS integration lines) are achieved, avoiding balance-sheet over-leverage before customer off-take agreements are finalized ^[6].

---

Strategic Implications

• Core Cash-Flow Funding: High operating profits from the traditional lead-acid business (which generated Rs 4,005.24 Crores of segment revenue in Q1 FY27) ^[2] continue to fund the negative cash flows and capital outlay of the New Energy division (which generated Rs 209.30 Crores of revenue in Q1 FY27 alongside ongoing initial operating losses) ^[2].
• Execution Watchpoints: Near-term capital efficiency will depend on customer validation timelines from the newly opened CQP line ^[6], initial operating margin achievement in the BESS line (guided at 6%–7% initially) ^[9], and execution timing on the first 2 GWh commercial Giga-1 line scheduled for Q1 FY28/June 2027 ^[9].***

The regulatory disclosure explicitly specifies the utilization of the Rs 550 Crores capital infusion, dividing it across two distinct wholly-owned subsidiaries with separate mandates ^[1].

• Amara Raja Advanced Cell Technologies Private Limited: An amount of Rs 500 Crores is earmarked to set up gigafactories and plants, supplementing an existing Rs 2,000 Crore approval ^[1]. This directly supports the infrastructure build-out for lithium-ion cell manufacturing and the broader Giga Corridor initiative.
• Amara Raja Power Systems Limited: An amount of Rs 50 Crores is earmarked to support further operational and manufacturing requirements, supplementing a prior Rs 50 Crore approval ^[1].

The disclosure differentiates capital allocation by directing the primary tranche toward long-term gigafactory infrastructure and the secondary tranche toward operational scaling.

Scale and Milestone Acceleration Analysis

The incremental board-approved investment of Rs 550 Crores on August 10, 2026 ^[1] represents 32.35% to 36.67% of Amara Raja Energy & Mobility’s (ARE&M) total capital expenditure guidance of Rs 1,500 Crores to Rs 1,700 Crores for FY27 ^[9].

This board approval expands the cumulative equity/loan commitment caps for subsidiaries rather than accelerating operational completion dates. Operational milestones for the flagship gigafactory remain unchanged, with Phase 1 (2 GWh capacity) targeted for commissioning in Q2 CY2027 (Q2 FY28) ^[9].

---

Incremental Capex vs. FY27 Capex Guidance

On August 10, 2026, the board approved an additional capital infusion of Rs 500 Crores into Amara Raja Advanced Cell Technologies (ARACT) and Rs 50 Crores into Amara Raja Power Systems (ARPSL) ^[1].

Key Analytical Takeaways:

• Share of Total FY27 Capex: The Rs 550 Crores incremental approval equates to 32.35% of the upper-bound FY27 capex guidance (Rs 1,700 Crores) and 36.67% of the lower-bound guidance (Rs 1,500 Crores), derived from reported figures ^[1].
• Share of New Energy Capex: Isolate ARACT’s incremental Rs 500 Crores against the guided Rs 1,100 Crores to Rs 1,200 Crores New Energy FY27 capex budget: it represents 41.67% to 45.45% of the segment's planned outlay for the year (derived from ^[1]).
• Expanded Capital Ceiling: Cumulative approved capital limits for ARACT rise from Rs 2,000 Crores to Rs 2,500 Crores, and ARPSL limits double from Rs 50 Crores to Rs 100 Crores ^[1]. Prior filings show Rs 1,500 Crores was already infused into ARACT through March 2026 ^[3].

---

Operational Milestone Timeline Comparison

The filing does not signal an acceleration of previously announced operational timelines. The capital expansion aligns directly with the previously stated phased commissioning plan for the Divitipally Gigafactory and assembly assets.

Timeline Execution Context:

• Execution Constraints: Management noted minor execution limits regarding technical equipment commissioning, specifically surrounding vendor engineering support from China, though in-house teams have taken direct control of the cylindrical 2170 program ^[9].
• Sequence intact: The progression remains structured in sequence: operationalizing customer qualification lines in Q2 FY27, followed by commercial Phase 1 (2 GWh) production in Q2 CY2027 (Q2 FY28) ^[9].

---

Strategic Implications

• Capital Allocation Runway: The board resolution secures formal financing authority to fund equipment procurement and site civil works through FY27 without requiring recurring board approvals for tranche disbursements ^[1].
• Subsidiary Operationalization: Doubling ARPSL's investment ceiling from Rs 50 Crores to Rs 100 Crores underlines growing capital requirements for power system integration, chargers, and operational hardware scaling alongside cell manufacturing ^[1].
• Margin Drag Management: New cell plant operations carry initial EBITDA margins of 6% to 7% during early ramp-up before targeting 10% to 11% at scale ^[5]. Capitalizing the buildout within pre-guided limits ensures cash flows from the legacy lead-acid business (targeting 13% to 14% EBITDA margins) comfortably absorb the new energy gestation phase ^[5].